Inovio Pharmaceuticals (INO) Stock Forecast & Price Target $5.70 +0.05 (+0.88%) (As of 12:57 PM ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Inovio Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 5 Analyst RatingsSell0Hold2Buy3 Based on 5 Wall Street analysts who have issued ratings for Inovio Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 2 have given a hold rating, and 3 have given a buy rating for INO. Consensus Price Target $43.80664.40% Upside According to the 5 analysts' twelve-month price targets for Inovio Pharmaceuticals, the average price target is $43.80. The highest price target for INO is $144.00, while the lowest price target for INO is $7.00. The average price target represents a forecasted upside of 664.40% from the current price of $5.70. Get the Latest News and Ratings for INO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Inovio Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up INO Analyst Ratings Over TimeTypeCurrent Forecast10/5/23 to 10/4/241 Month Ago9/5/23 to 9/4/243 Months Ago7/7/23 to 7/6/241 Year Ago10/5/22 to 10/5/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)3 Buy rating(s)0 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)1 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$43.80$44.00$70.67$288.00Forecasted Upside664.40% Upside569.20% Upside691.34% Upside459.13% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyReduce Who are Nvidia’s New Silent Partners? (Ad)Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” INO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History INO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Inovio Pharmaceuticals Stock vs. The CompetitionTypeInovio PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.60 2.78 2.50Consensus RatingModerate BuyModerate BuyHoldPredicted Upside678.76% Upside850.33% Upside7.73% UpsideNews Sentiment RatingNeutral NewsSee Recent INO NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails10/4/2024Royal Bank of Canada4 of 5 stars Lower TargetSector Perform ➝ Sector Perform$8.00 ➝ $7.00+21.32%8/12/2024Oppenheimer3 of 5 stars Lower TargetOutperform ➝ Outperform$40.00 ➝ $33.00+294.74%7/15/2024HC Wainwright2 of 5 stars Reiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.00+32.63%5/14/2024StephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingS. LoganathanSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$20.00+76.06%1/4/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageMarket Outperform$144.00+92.09%11/9/2022Maxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Hold11/1/2022Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeNeutral ➝ Underperform$288.00-7.41%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:14 PM ET. INO Forecast - Frequently Asked Questions What is Inovio Pharmaceuticals' forecast for 2024? According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Inovio Pharmaceuticals is $43.80, with a high forecast of $144.00 and a low forecast of $7.00. Should I buy or sell Inovio Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INO shares. Does Inovio Pharmaceuticals's stock price have much upside? According to analysts, Inovio Pharmaceuticals's stock has a predicted upside of 668.42% based on their 12-month stock forecasts. What analysts cover Inovio Pharmaceuticals? Inovio Pharmaceuticals has been rated by research analysts at HC Wainwright, Oppenheimer, and Royal Bank of Canada in the past 90 days. Do Wall Street analysts like Inovio Pharmaceuticals more than its competitors? Analysts like Inovio Pharmaceuticals less than other "medical" companies. The consensus rating score for Inovio Pharmaceuticals is 2.60 while the average consensus rating score for "medical" companies is 2.78. Learn more on how INO compares to other companies. Stock Forecasts and Research Tools Related Companies: SIBN Stock Forecast SRDX Stock Forecast FNA Stock Forecast TMCI Stock Forecast CERS Stock Forecast TCMD Stock Forecast LUNG Stock Forecast SGHT Stock Forecast CLPT Stock Forecast RCEL Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Trade Alongside Pelosi, Buffett, and More (Ad)People don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, Bill Ackman, Steve Cohen and more. They also don’t know that they can learn how it’s done and receive daily, AI powered trade alerts for free! All because of one trading veteran that set up a free newsletter designed to level the playing field.Sign up takes less than 10 seconds, and you’ll start getting his alerts and market insights absolute This page (NASDAQ:INO) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
